Bellerophon Therapeutics (BLPH)
(Delayed Data from OTC)
$0.04 USD
0.00 (0.00%)
Updated Aug 6, 2024 11:56 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Bellerophon Therapeutics, Inc. [BLPH]
Reports for Purchase
Showing records 21 - 37 ( 37 total )
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2/3 INOpulse Cohort 2 Topline Data Supportive of Phase 3 Initiation Planned for 2020; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Cohort 2 Data Can Offer Incremental Clarity Into Pivotal Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lung Disease KOL Offers Insights Into Actigraphy, Emergent Patient Activity Metric; Reit Buy and $3PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Full Steam Ahead With PH-ILD Program; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory Clarity Positions INOpulse Well as Potential First Approved Therapy for PH-ILD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive INOpulse Phase 2b Interim Data Supports Actigraphy as Clinical Endpoint
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Remain Bullish Ahead of Impending Interim Phase 3 PAH Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes Remain on INOvation-1; Reit Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to Data Catalysts This Year; Reit Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PH-COPD Top Line Builds Upon INOpulse?s Clinical Potential: Reit Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Believe KOL Focus on PH-ILD Signals Right Strategy Going Forward: Reit Buy Rating and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from IPF and COPD Posters: V/Q Mismatch Prevention and Composite Endpoint May Suggest Long-Term Benefit
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preview of Phase 2 PH-COPD and PH-IPF on Tap for Early 2017
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Power of NO for PAH: Initiating with Buy Rating and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A